|
|
Jil C. Tardiff
J Clin Invest. 2006;
116(6):1467
doi:10.1172/JCI28884
Abstract |
Full text
| PDF

T
he question of what differentiates physiological from pathological cardiac hypertrophy remains one of the most clinically relevant questions in basic cardiovascular research. The answer(s) to this question will have far-ranging importance in the fight against hypertrophic heart disease and failure. In this issue of the JCI, Perrino et al. have used a unique model system to mimic the pathophysiologic effects of an intermittent pressure overload on the heart — in effect, to examine the basic issue of what determines an in vivo pathogenic stimulus (see the related article beginning on page 1547). Their findings clearly show that it is the nature of the inciting stimulus, as opposed to chronicity, that establishes the initial pathogenic response and that a distinct disruption of the β-adrenergic system is centrally involved in the earliest alterations of myocellular physiology. These results suggest both a new paradigm for treatment options in hypertrophic cardiac disease and novel methodologies for further studies.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(2)
| Title and authors |
Publication |
Year |
Angiotensin-(1–9) regulates cardiac hypertrophy in vivo and in vitro
Maria Paz Ocaranza, Sergio Lavandero, Jorge E Jalil, Jaqueline Moya, Melissa Pinto, Ulises Novoa, Felipe Apablaza, Leticia González, Carol Hernández, Manuel Varas, René López, Iván Godoy, Hugo Verdejo, Mario Chiong
|
Journal of Hypertension
|
2010 |
Rosuvastatin inhibits norepinephrine-induced cardiac hypertrophy via suppression of Gh
Eui-Young Choi, Woochul Chang, Soyeon Lim, Byeong-Wook Song, Min-Ji Cha, Hye-Jung Kim, Eunju Choi, Yangsoo Jang, Namsik Chung, Ki-Chul Hwang
|
European Journal of Pharmacology
|
2010 |
|